ORUKA THERAPEUTICS INC (ORKA) Stock Income Statement
USA - NASDAQ:ORKA - US6876041087 - Common Stock
28.23 USD
+1.15 (+4.25%)
28.23 USD
0 (0%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 113.28M | 88.12M | 7.30M | 10.60M | 19.34M | |||
| Research and Development | 95.21M | 75.06M | 1.01M | 4.75M | 13.83M | |||
| Selling, General, and Administrative Expenses | 18.08M | 13.06M | 6.28M | 5.85M | 5.50M | |||
| Operating Income | -113.28M | -88.12M | -7.30M | -10.60M | -19.34M | |||
| Interest Income/Expense | 13.31M | 4.39M | 1.96M | 675.00K | 13.00K | |||
| Other Income/Expense | null | 4.00K | 0 | -5.00K | null | |||
| Non Recurring Items | null | null | null | null | null | |||
| Income Before Taxes | -99.98M | -83.72M | -5.34M | -9.93M | -19.32M | |||
| Income Tax | null | null | null | null | 0 | |||
| Net Income | -99.98M | -83.72M | -5.34M | -9.93M | -19.32M | |||
| EBITDA | -113.25M | -88.10M | -7.28M | -10.58M | -19.32M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.5819 | -4.9867 | -4.4443 | -8.2659 | -16.6769 | |||
| Non GAAP EPS | -2.81 | null | null | null | null | |||
| Statistics | ||||||||
All data in USD